USA flag logo/image

An Official Website of the United States Government

Antibodies Against Amyloid Beta-Protein Intermediates

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65826
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
AG022759
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
New England Rare Reagents
3 Burnham Road Gorham, ME 04038 1906
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Antibodies Against Amyloid Beta-Protein Intermediates
Agency: HHS
Contract: 1R43AG022759-01
Award Amount: $106,615.00
 

Abstract:

DESCRIPTION (provided by applicant): Recent data from several labs suggest that intermediates formed during fibril formation, referred to as protofibrils (PFs), may contribute to neuronal injury in Alzheimer's disease (AD). Currently, there are no antibodies in the marketplace that can distinguish these abnormal oligomeric protofibrils from the normal occurring monomeric ABeta peptide. New England Rare Reagents in collaboration with Brigham and Women's Hospital seeks Phase I funding to assist with the development of antibodies to protofibrillular ABetaPeptide mimetics of ABeta intermediate assemblies can be rationally designed and used as immunogens to generate conformationally restricted antibodies. As proof of concept, we have shown previously that cyclized peptides derived from a region within the bovine pfion protein sequence was able to generate conformation-specific antibodies. Following this lead we propose to: (1) Synthesize cyclized peptides derived from the ABeta sequence where Beta sheet associations may form and conjugate with T-cell epitope peptides. (2) Immunize animal with peptide conjugates and screen serum by ELISA for cyclized and un-cyclized peptide specificity. (3) Isolate clones specific for cyclized peptides and generate monoclonal antibody supernatants. (4) Confirmation of antibody specificity to ABeta PFs by Western blotting and immuno-electron microscopy. The commercialization goals for these reagents are to generate monoclonal antibodies that will recognize the Beta-sheet form of ABeta that could be used for research purposes to identify and understand protofibrils pathophysiology in AD or other abnormal protein-folding diseases. Additionally, if protofibrils form in humans, these novel antibodies may be valuable in identifying these assemblies in blood and/or tissues, helping to diagnose early stages of AD. Moreover, if PFs play an important role in the early pathogenesis of AD these antibodies may be useful for passive immunization, or to identify potential peptide vaccine immunogens. For these reasons we strongly feel these antibodies will be of high commercial value if available to the research community or other commercial enterprises. Generation and initial characterization of these antibodies in this phase will be the foundation for further in vitro and in vivo characterization in Phase II, as well as the scale-up of the antibody production.

Principal Investigator:

Robert L. Lawton
2078394410
OPB@MAINE.RR.COM

Business Contact:


2077415070
Small Business Information at Submission:

NEW ENGLAND RARE REAGENTS
NEW ENGLAND RARE REAGENTS 3 BURNHAM RD GORHAM, ME 04038

EIN/Tax ID: 320032289
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No